With
over 29 million Americans living with diabetes, and more than 86 million with
prediabetes, this disease is the seventh leading cause of death and swallows
approximately 20% of nationwide healthcare spending, according to Centers for
Disease Control and Prevention (CDC) statistics (http://nnw.fm/uUEx3).
Healthcare officials, patients and doctors alike are always actively searching
for new therapies or innovative yet affordable treatments to combat this
disease.
This
is where leading biopharmaceutical company MannKind Corporation (NASDAQ: MNKD)
and its groundbreaking inhalable insulin product Afrezza® come in. Touted as
the first successful insulin inhaler on the U.S. market, Afrezza is a
fast-acting inhalable insulin powder designed to be used in conjunction with
regular type 1 and 2 diabetes treatments to help lower post-meal blood sugar
spikes.
Beginning
in July, MannKind relaunched Afrezza Inhalation Powder on the domestic market
under its own branding, and the treatment is now available with major
wholesalers, as well as by prescription in any retail pharmacy.
Leveraging
its two-year experience in patient selection and copayment, the company has
also announced several programs to promote patients’ access to Afrezza therapy.
These include:
Enhanced
copay assistance designed to lower insured patients’ out-of-pocket cost to $15
per month
Patient
reimbursement support program, MannKind Cares
Bureau
to educate and inform healthcare providers about the benefits of Afrezza
New
titration pack that allows patients new to Afrezza more flexibility in
adjusting their daily dosage
The
new programs will join MannKind’s national salesforce, all of whom have
extensive experience with diabetes and Afrezza, in its efforts to help enhance
and streamline patients’ and providers’ experience with this key therapy. The
company is committed to ensuring the treatment remains available to all
diabetes patients in the U.S., without any disruption in supply.
The
July relaunch came after the company released six more analyses of the pre-meal
treatment, demonstrating a faster onset and shorter duration of action than
with mealtime fast-acting insulin treatments. The findings, presented at the
76th scientific session of the American Diabetes Association, show that,
compared to Eli Lilly and Company’s (NYSE: LLY) insulin lispro injection,
Afrezza has a 50% faster onset and a 2-3-hour shorter duration of action.
The
data supports the use of this therapy for rapidly controlling high glucose
levels, according to the chief medical officer of MannKind, Raymond W.
Urbanski, MD, PhD. Unlike injectable insulin, which risks causing hypoglycemia
after a meal if dosed incorrectly, Afrezza works in the body more rapidly and
leaves the bloodstream faster, offering an ideal balance between glucose
control and a lower risk of hypoglycemia.
To
find out more about MannKind Corp. and its innovative Afrezza Inhalation Powder
insulin, visit www.MannkindCorp.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
